Living with type 1 diabetes? Get essential tips, relatable insights, and support tailored for Singaporean parents! Here's to living fully and thriving! #Type1Diabetes ...

The page covers everything you need to know about student budgeting from tips on how to work out your budget and how you can make your money stretch further month by month.

If you’ve been following me on social media since I launched my blog 11 years ago, then you know that I’m all about a meal plan situation. From just about the beginning of What’s Gaby Cooking, I’ve ...

Diet-to-Go meal costs vary based on the plan. The Balance, Balance-Diabetes, and Vegetarian plans range between $18 and $29 per day, while the Keto-Carb30 plan ranges between $21 and $29 per day.

Lilly shares were off 8%, wiping out nearly $70 billion from the Indianapolis-based drugmaker's market value. Both its weight-loss drug Zepbound and diabetes treatment Mounjaro have been ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

AnaptysBio (NASDAQ:ANAB), which is advancing an arthritis therapy similar to Eli Lilly's (NYSE:LLY) PD-1 agonist peresolimab, sold off in the premarket on Wednesday after the Indiana-based pharma ...

At the core of the disappointing results were weaker-than-expected revenue from Eli Lilly’s GLP-1 drug tirzepatide sold under the brand names Mounjaro for type 2 diabetes and Zepbound for weight ...

What's behind Lilly's disappointing Q3 update? Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year ...

However, Eli Lilly continued to develop GLP-1 drugs, getting Trulicity, which is used to treat type 2 diabetes, approved in 2014. By 2018, Trulicity would become Eli Lilly's top-selling drug ...